Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach that allows for significantly increased local drug concentrations and improved tumor penetration to achieve improved clinical treatment efficacy.

The lead candidate THE001 is a thermosensitive formulation of doxorubicin. It enables intravascular drug release initiated by a mild heat trigger using clinical hyperthermia devices. This results in an up to 15-fold higher local tumor drug concentrations and aims to improve clinical treatment efficacy by creating a local boost. These high local concentrations, which also reach less well perfused areas, aim to overcome drug resistance. The first clinical indication of THE001 is soft tissue sarcoma.